TGFB1 and colorectal carcinoma: Although previous studies targeting TGFβ in CRC have only provided limited results, especially due to systemic effects, resent data suggest that the inhibition of the TGFβ pathway in selected patients or in combination with the immune checkpoint blockade might be promising strategies.